More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$68.22B
EPS
0.21
P/E ratio
84.1
Price to sales
2.02
Dividend yield
2.856%
Beta
-0.031153
Previous close
$21.43
Today's open
$21.73
Day's range
$21.56 - $21.86
52 week range
$13.91 - $21.86
show more
CEO
Julie Kim
Employees
47029
Headquarters
Tokyo,
Exchange
New York Stock Exchange
Shares outstanding
3.16B
Issue type
American Depository Receipt
Healthcare
Pharmaceuticals
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda said on Thursday its narcolepsy pill, the first treatment to target the underlying cause of the rare sleep disorder, is now available in the US after a Drug Enforcement Administration decision removed the final regulatory hurdle for its rollout.
Reuters • Nov 12, 2026

Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States.
Business Wire • Nov 12, 2026

What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability.
MarketBeat • Oct 30, 2026

Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow
Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but operating cash flow declined to $2.74B, highlighting weak underlying cash generation. New products like Mimrylo and Orzeyful are slow to ramp and currently contribute minimally, while Entyvio remains the key revenue driver.
Seeking Alpha • Oct 30, 2026

Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical Co Ltd (NYSE:TAK) on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the consensus of 31 cents.
Benzinga • Oct 29, 2026

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Seeking Alpha • Oct 29, 2026

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeline. Takeda's focus remains on execution against the first horizon of its growth strategy: succe.
Business Wire • Oct 29, 2026

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical On.
Business Wire • Oct 23, 2026

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent.
Business Wire • Oct 19, 2026

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.
Business Wire • Oct 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) commission-free¹. Build wealth for the long term using automated trading and transfers.